Index of Current Clinical Trials

 Listed below are study summaries of the clinical trials SDCRI is presently supporting. (Programs for prostate cancer and brain tumors are under development).

1. Breast Cancer
2. Colorectal Cancer
3. Low Grade Non-Hodgkin's Lymphoma
4. Non-Small Cell Lung Cancer (NSCLC)
5. Prostate Cancer

Low Grade Non-Hodgkin's Lymphoma

1. A Phase II Open-Label Research Study Using Standard Therapy in Combination with a Tumor Specific Immunotherapy

Target Patient Population:
· Low Grade Non-Hodgkin's Lymphoma (NHL)
· Patients may have receive 0 to 2 prior therapies for their disease
· Patients must have a site of disease that is accessible for biopsy.
· Patients must not be resistant to Rituxan

The patient will have a vaccine-like therapy developed from their own tumor tissue that will be used to create an immunotherapy. This Tumor Specific immunotherapy will be used in combination with standard treatment.

Please contact Christine DeFrancisco at 760-598-1700 for more details.

2. A Phase IV Open-Label Research Study Using Standard Chemotherapy in Combination with Rituxan

Target Patient Population:
· Low Grade Non-Hodgkin's Lymphoma (NHL)
· Patients must have not had previous treatment for NHL
· Patients must be eligible for chemotherapy
· Patients must have stage 3 or 4 disease

The patient will have standard chemotherapy in combination with Rituxan treatment for a total of approximately 5 months followed by Rituxan maintenance treatment for a total of 2 years.

Please contact Christine DeFrancisco at 760-598-1700 for more details.

3. A Phase IV Open-Label Research Study Using Standard Chemotherapy in Combination with Rituxan

Target Patient Population:
· Diffuse Large Cell or Follicular Center Cell Non-Hodgkin's Lymphoma (NHL)
· Patients must have not had previous treatment for NHL
· Patients must be eligible for chemotherapy
· Patients must have Stage II Bulky Disease, Stage 3 or Stage 4

The patient will have standard chemotherapy in combination with Rituxan treatment for a total of approximately 5 months followed by Rituxan maintenance treatment for a total of 2 years.

Please contact Christine DeFrancisco at 760-598-1700 for more details.

4. A Phase II Trial using a Novel Agent Plus Rituxan

Target Patient Population:
· Patients must have recurrent or refractory low-grade CD20+ B-Cell Non-Hodgkin's Lymphoma (NHL) with measurable disease confirmed by CT scan.
· Patients must have received one prior chemotherapy regimen for NHL
· Patients may not have received prior antibody therapy for lymphoma (other than Rituxan)
· Patients may not have known HACA/HAHA positivity.

The patient will receive a novel agent in combination with weekly Rituxan. This is an open-label, non-randomized research study, therefore all patients receive the same treatment and know the treatment they are receiving.